BeiGene, Ltd. ( BGNE) - Key Metrics
Stock symbol BGNE is outdated, potentially delisted? Maybe it is available on other exchange?
BGNE Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2024Q3 | $9.46 | -$1.15 | $1.78 | $0.52 |
| 2024Q2 | $8.87 | -$1.15 | -$0.91 | -$1.96 |
| 2024Q1 | $5.55 | -$1.85 | -$2.28 | -$3.47 |
| 2023Q4 | $6.10 | -$3.53 | -$2.13 | -$3.73 |
| 2023Q3 | $7.46 | $2.06 | -$0.75 | -$2.49 |
BGNE Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2024Q3 | ? | -48.98 |
| 2024Q2 | ? | -31.50 |
| 2024Q1 | ? | -21.49 |
| 2023Q4 | ? | -12.77 |
| 2023Q3 | ? | 21.85 |
BGNE Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2024Q3 | 0.23% | ? |
| 2024Q2 | -1.35% | ? |
| 2024Q1 | -2.18% | ? |
| 2023Q4 | -2.07% | ? |
| 2023Q3 | -1.38% | ? |
BGNE
Price: $184.71
52 week price:
Earnings Per Share: -8.19 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: Cayman Islands
Volume: 346500
Ebitda: 116.2 millionMarket Capitalization: 20.2 billion